Here's Why Merck Paid Triple the Price for Idenix

Merck pays a hefty price for hepatitis C specialist Idenix Pharmaceuticals.

Jun 9, 2014 at 7:00PM
Longview

U.S. stocks put in another record high on Monday -- the ninth in 11 trading sessions -- as the benchmark S&P 500 and the narrower Dow Jones Industrial Average (DJINDICES:^DJI) both rose 0.1%. The technology-heavy Nasdaq Composite Index (NASDAQINDEX:^IXIC) gained 0.4%.

Although companies are reluctant to dip into their cash piles to make capital expenditures, mergers and acquisitions are back in vogue, with health care one of the busiest sectors. Large pharmaceutical firms are willing to buy growth, and they're seemingly not afraid to pay up for it, either. Today, it was the turn of Merck (NYSE:MRK) to announce that it has agreed to acquire Idenix Pharmaceuticals (NASDAQ:IDIX) with an all-cash offer of $24.50 per share -- more than three times Friday's closing price of $7.23. The transaction values the hepatitis C specialist at $3.85 billion.

Merck

Source: Wikipedia.

Merck is eyeing with envy the payday Gilead Sciences has hit with hepatitis C drug Sovadi. As the Financial Times pointed out today, Sovadi is well on its way to becoming the most successful drug launch in history, having racked up a whopping $2.3 billion in revenue in its first three months on the market.

Merck isn't alone. Hepatitis C is considered to be one of the most promising areas for drug development, and though Gilead has grabbed the lead, the field is intensely competitive. In April, AbbVie (NYSE:ABBV) published late-stage trial results for a drug cocktail that cured over 90% of patients with the recalcitrant GT1 strain of hepatitis C after just 12 weeks. Merck wants to combine an Idenix drug with two of its own to create a cocktail that might cure most strains of hepatitis within two months, although Merck expects to commercialize its two-drug regimen first (assuming phase 3 trials are successful).

Last week, I made a reference to the Baupost Group, which is led by Seth Klarman, probably the greatest investor you've never heard of. It turns out that the hedge fund group is one of the big winners in this deal, being the largest shareholder of Idenix, with 35% of the shares outstanding at the end of March.

Baupost acquired nearly a third of that stake at the end of January in a direct offering at a price of $6.50; as of today's close, that operation has generated a 266% return -- not bad for a holding period that barely exceeds four months. There is no use complaining that you don't have access to a direct offering the way Baupost does, either -- individual investors could have purchased shares below $6.50 as recently as May 30.

However, Baupost is no fast-buck artist. The hedge fund manager has owned shares of Idenix since the second quarter of 2011. Furthermore, the portfolio manager had to display steely nerves to hold them through periods of massive volatility -- over the past three years, the shares have risen to above $14 before falling below $4 (multiple times).

Baupost has made out superbly owning Idenix, but will Merck be able to say the same thing in several years' time? Price paid is a key determinant of your ultimate return, and by that standard, Merck has set itself a high hurdle. (For more on this topic, read why my Foolish colleague George Budwell doesn't like the deal.)

Beyond Merck: Invest in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Alex Dumortier, CFA, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers